MSB (ASX) Ann: Mesoblast Update on Chronic Low Back Pain Program

Originally posted by stockrock ↑

Type C meeting with the FDA on CLBP results was scheduled for July/Aug... they didn't submit the request today, Silviu mentioned in the stem cell summit (at 32:55 see below video) which means they requested the Type C meeting sometime in June would be my best guess "we will be having discussions also in the next couple of months"... were his exact words.

US$150m was the original amount of upfront and milestone payments, which has now been reduced to US$112.5m. US$37.5m reduction probably due to US$20 milestone on EU approval to start EU trial no longer applicable, as well as other milestones related to the EU trial which are now not applicable.

This means that the EU regulator has given Grunenthal the green light that a US trial with only 20% participants from the EU would be sufficient for approval. We won't know what was discussed, but the regulator does not make the hurdles to approval less stringent if it wasn't impressed with the data it has seen thus far... the undeniable reduction in pain, and the reduction in opioid use (even after patients and doctors were told to not change their medication throughout the trial) speaks volumes on how effective this is.

On the US FDA meeting, IMO this is going to be a trigger for partners in the US to come forward. All the potential partners need to hear is that a confirmatory trial showing the same benefit in pain, and possibly a key secondary endpoint of reduction in opioid use.. would be sufficient for product approval. Function improvement whilst important, IMO has been overtaken by opioid abuse as a secondary key determinant of whether a therapy would be beneficial to a patient in the current medical field. I believe a US partner will be signed on to run and fund the US trial.. and with the Surgcentre network at their disposal, it is going to be a very efficiently recruited trial IMO.

I still think there is a chance of accelerated approval on the reduction in opioid use as a surrogate endpoint.. but this largely depends on whether or not the FDA consider opioid abuse as a serious condition that would warrant accelerated approval. A serious condition is defined as 'life-threatening' ... so whilst there is some increased focus on opioid abuse at the agency, I haven't seen anything given accelerated approval for opioid abuse. So with anything where it's a first... I would place only a small probability of success, and this is the case here for me. But as always, I'm hoping to be pleasantly surprised, as I know Mesoblast will be enquiring if this path of approval will be available to them, because the data is extremely impressive when it comes to reduction in opioid use.

Expand

Thanks @stockrock ..... you would think MSB, Grunenthal and possibly even SurgCenter would attempt to leverage off reports like the following in support of the serious condition and / or 'life threatening' argument ?

GLTAH

https://www.ama-assn.org/system/files/2020-12/issue-brief-increases-in-opioid-related-overdose.pdf

Issue brief: Drug overdose epidemic worsened during COVID pandemic *Updated June 1, 2021

https://www.delawarepublic.org/post/overdose-deaths-surged-pandemic-more-drugs-were-laced-fentanyl

Overdose Deaths Surged In Pandemic, As More Drugs Were Laced With Fentanyl

https://www.washingtonpost.com/poli...2-overdose-deaths-may-have-topped-90000-2020/

The Health 202: Overdose deaths may have topped 90,000 in 2020

No.	Vol.	Price($)
2	25589	$1.13

No.

Vol.

Price($)

25589

$1.13

Price($)	Vol.	No.
$1.13	10000	1

Price($)

Vol.

No.

$1.13

10000

No.	Vol.	Price($)
2	25589	1.125
16	303483	1.120
2	136703	1.115
9	203201	1.110
3	61500	1.105

No.

Vol.

Price($)

25589

1.125

303483

1.120

136703

1.115

203201

1.110

61500

1.105

Price($)	Vol.	No.
1.130	10000	1
1.135	20000	1
1.140	60630	4
1.145	29630	2
1.150	93731	8

Price($)

Vol.

No.

1.130

10000

1.135

20000

1.140

60630

1.145

29630

1.150

93731

(20min delay)
Last $1.13		Change -0.055(4.66%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.18	$1.18	$1.13	$4.824M	4.236M

Ann: Mesoblast Update on Chronic Low Back Pain Program, page-58

AI stocks: What to expect in 2024-25

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Mesoblast Update on Chronic Low Back Pain Program, page-58

Top Stories

AI stocks: What to expect in 2024-25

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News